WO2024175985 - DEVELOPMENT OF TRIMETHYLLYSINE HYDROXYLASE (TMLH) INHIBITORS
National phase entry:
Publication Number
WO/2024/175985
Publication Date
29.08.2024
International Application No.
PCT/IB2023/061218
International Filing Date
07.11.2023
Title **
[English]
DEVELOPMENT OF TRIMETHYLLYSINE HYDROXYLASE (TMLH) INHIBITORS
[French]
DÉVELOPPEMENT D'INHIBITEURS DE TRIMÉTHYLLYSINE HYDROXYLASE (TMLH)
Applicants **
LATVIAN INSTITUTE OF ORGANIC SYNTHESIS
Aizkraukles street 21
LV-1006 Riga, LV
Inventors
ARSENJANS, Pavels
Vangazu street 30-45
LV-1024 Riga, LV
LIEPINS, Edgars
Brivibas street 192-31
LV-1012 Riga, LV
DAMBROVA, Maija
Aleksandra Grina bulvaris 15-7
LV-1002 Riga, LV
GRANDANE, Aiga
Atputas iela 2-3
LV-1076 Valdlauci Kekavas pag., LV
ZELENCOVA-GOPEJENKO, Diana
Ozolciema iela 14 k-1-22
LV-1058 Riga, LV
GRINBERGA, Solveiga
Dienvidu iela 7 k-3-50
LV-2169 Salaspils, LV
Priority Data
LVP2023000017
20.02.2023
LV
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 973 | |
| EPO | Filing, Examination | 4526 | |
| Japan | Filing | 591 | |
| South Korea | Filing | 574 | |
| USA | Filing, Examination | 3310 |
Total: 9,974 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present invention relates to a novel N-aryl lysine derivatives and isosteres as cardioprotective agents by inhibiting trimethyllysine hydroxylase (TMLH) activity, as well as methods of their manufacturing and use in different pharmaceutical compositions for the treatment of various diseases and disorders by administration of such substances.[French]
La présente invention concerne de nouveaux dérivés de N-aryl lysine et des isostères en tant qu'agents cardioprotecteurs par inhibition de l'activité de la triméthyllysine hydroxylase (TMLH), ainsi que leurs procédés de fabrication et d'utilisation dans différentes compositions pharmaceutiques pour le traitement de diverses maladies et divers troubles par administration de telles substances.